In one study evaluating the combination of erlotinib plus nivolumab, durable tumor regression in both treatment (TKI or chemotherapy) naïve and TKI-treated patients was reported [17] and there are several additional trials evaluating the efficacy of combining PD-1/PD-L1 inhibitors with EGFR TKIs [13]. The gene discussed is EGFR; the disease is neoplasm.